➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Moodys
McKesson
McKinsey
Johnson and Johnson

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 10,507,262

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,507,262
Title:Biocompatible hydrogel treatments for retinal detachment
Abstract: Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.
Inventor(s): Askari; Syed H. (San Jose, CA), Choi; Yeon S. (Emeryville, CA)
Assignee: C.P. MEDICAL CORPORATION (Norcross, GA)
Application Number:15/467,019
Patent Claims:see list of patent claims

Details for Patent 10,507,262

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial C.P. MEDICAL CORPORATION (Norcross, GA) 2032-05-11 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial C.P. MEDICAL CORPORATION (Norcross, GA) 2032-05-11 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12   Start Trial C.P. MEDICAL CORPORATION (Norcross, GA) 2032-05-11 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 002 1998-05-12   Start Trial C.P. MEDICAL CORPORATION (Norcross, GA) 2032-05-11 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial C.P. MEDICAL CORPORATION (Norcross, GA) 2032-05-11 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial C.P. MEDICAL CORPORATION (Norcross, GA) 2032-05-11 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial C.P. MEDICAL CORPORATION (Norcross, GA) 2032-05-11 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
McKinsey
Express Scripts
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.